

# Austin G Duffy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048845/publications.pdf>

Version: 2024-02-01

20  
papers

6,619  
citations

567281

15  
h-index

839539

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

12564  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
2	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	3.7	624
3	The yin and yang of evasion and immune activation in HCC. <i>Journal of Hepatology</i> , 2015, 62, 1420-1429.	3.7	274
4	Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 1757-1765.	4.1	245
5	Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. <i>United European Gastroenterology Journal</i> , 2013, 1, 351-357.	3.8	93
6	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	7.3	77
7	Colorectal Cancer Survival Gains and Novel Treatment Regimens. <i>JAMA Oncology</i> , 2015, 1, 787.	7.1	75
8	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 299-307.	4.2	58
9	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2318-2326.	7.0	54
10	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. <i>Cancer Immunology Research</i> , 2015, 3, 557-566.	3.4	44
11	Regorafenib as second-line therapy in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 141-142.	17.8	26
12	The case for immune-based approaches in biliary tract carcinoma. <i>Hepatology</i> , 2016, 64, 1785-1791.	7.3	25
13	Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. <i>Hepatology</i> , 2013, 57, 1068-1077.	7.3	24
14	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	3.7	22
15	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. <i>Targeted Oncology</i> , 2009, 4, 267-273.	3.6	20
16	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50.	4.2	10
17	Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?. <i>Hepatic Oncology</i> , 2016, 3, 183-185.	4.2	2
18	Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. <i>American Journal of Therapeutics</i> , 2010, 17, 79-85.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies.. Journal of Clinical Oncology, 2012, 30, 228-228.	1.6	0
20	Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome. BJR   case Reports, 2022, 8, .	0.2	0